| Serial Number | 79293279 |
| Word Mark | LIMINAL BIOSCIENCES |
| Filing Date | Friday, April 17, 2020 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, July 20, 2021 |
| Registration Number | 6422386 |
| Registration Date | Tuesday, July 20, 2021 |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, May 4, 2021 |
| Indication of Colors claimed | The color(s) teal, light green and gray is/are claimed as a feature of the mark. |
| Disclaimer with Predetermined Text | "BIOSCIENCES" |
| Description of Mark | The mark consists of two interlocking incomplete triangles in gradients of teal and light green to the left of a vertical gray line and the wording "LIMINAL BIOSCIENCES" in gray. The color white represents background and is not a feature of the mark. |
| Goods and Services | Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of asthma; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of dandruff; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; anti-viral agents; antibiotics; antivirals; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hypercholesterolemia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely, diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident, stroke, Parkinson's disease, multiple sclerosis, myasthenia gravis |
| Goods and Services | Manufacture of pharmaceuticals to the order and specification of others |
| Goods and Services | Development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development; pharmaceutical research services; research on the subject of pharmaceuticals |
| Goods and Services | Pharmaceutical advice; pharmaceutical consultancy services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing information to patients in the field of administering medications; medical care services relating to patient treatment, excluding services in the field of psychology and mental health |
| Goods and Services | Providing personal support services for families of patients with life threatening disorders, namely, emotional counseling and emotional support, and coordinating the procurement and administration of medication; providing companionship services for families of patients with life threatening disorders |
| Pseudo Mark | LIMINAL BIOSCIENCES |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 11, 2020 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 11, 2020 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 11, 2020 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 11, 2020 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 11, 2020 |
| Primary Code | 045 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Liminal BioSciences Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | CA |
| Party Name | Liminal BioSciences Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | CA |
| Party Name | Liminal BioSciences Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | CA |
| Event Date | Event Description |
| Sunday, December 26, 2021 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Friday, November 26, 2021 | FINAL DISPOSITION NOTICE SENT TO IB |
| Friday, November 26, 2021 | FINAL DISPOSITION PROCESSED |
| Wednesday, October 20, 2021 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Tuesday, July 20, 2021 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, May 4, 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, May 4, 2021 | PUBLISHED FOR OPPOSITION |
| Sunday, May 2, 2021 | NOTIFICATION PROCESSED BY IB |
| Wednesday, April 14, 2021 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, April 14, 2021 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, April 14, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, March 29, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, March 29, 2021 | EXAMINER'S AMENDMENT ENTERED |
| Monday, March 29, 2021 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, March 29, 2021 | EXAMINERS AMENDMENT E-MAILED |
| Monday, March 29, 2021 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, March 22, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Sunday, March 21, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Sunday, March 21, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, October 19, 2020 | REFUSAL PROCESSED BY IB |
| Thursday, October 1, 2020 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Wednesday, September 30, 2020 | REFUSAL PROCESSED BY MPU |
| Tuesday, September 15, 2020 | APPLICATION FILING RECEIPT MAILED |
| Sunday, September 13, 2020 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Saturday, September 12, 2020 | NON-FINAL ACTION WRITTEN |
| Friday, September 11, 2020 | ASSIGNED TO EXAMINER |
| Friday, September 11, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Thursday, September 10, 2020 | SN ASSIGNED FOR SECT 66A APPL FROM IB |